Cargando…
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773589/ https://www.ncbi.nlm.nih.gov/pubmed/36544222 http://dx.doi.org/10.1186/s40364-022-00445-6 |
| _version_ | 1784855225141559296 |
|---|---|
| author | Sun, Hao Li, Yingmei Zhang, Peng Xing, Haizhou Zhao, Song Song, Yongping Wan, Dingming Yu, Jifeng |
| author_facet | Sun, Hao Li, Yingmei Zhang, Peng Xing, Haizhou Zhao, Song Song, Yongping Wan, Dingming Yu, Jifeng |
| author_sort | Sun, Hao |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9773589 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97735892022-12-23 Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives Sun, Hao Li, Yingmei Zhang, Peng Xing, Haizhou Zhao, Song Song, Yongping Wan, Dingming Yu, Jifeng Biomark Res Correction BioMed Central 2022-12-21 /pmc/articles/PMC9773589/ /pubmed/36544222 http://dx.doi.org/10.1186/s40364-022-00445-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Sun, Hao Li, Yingmei Zhang, Peng Xing, Haizhou Zhao, Song Song, Yongping Wan, Dingming Yu, Jifeng Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives |
| title | Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives |
| title_full | Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives |
| title_fullStr | Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives |
| title_full_unstemmed | Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives |
| title_short | Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives |
| title_sort | correction: targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773589/ https://www.ncbi.nlm.nih.gov/pubmed/36544222 http://dx.doi.org/10.1186/s40364-022-00445-6 |
| work_keys_str_mv | AT sunhao correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives AT liyingmei correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives AT zhangpeng correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives AT xinghaizhou correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives AT zhaosong correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives AT songyongping correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives AT wandingming correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives AT yujifeng correctiontargetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives |